Autopsy report · NCT01987908

Evaluation of Different Dose Regimens of Aes-103 Given for 28 Days to Subjects With Stable Sickle Cell Disease

“Study was terminated early by the Sponsor due to unblinding between study drug and placebo groups at the subject, site and Sponsor levels.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 month before it started.
• Ran for about 1 year 3 months before it stopped.
• 35 participants enrolled.
• Results were posted on the registry 2 years after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Baxalta now part of Shire

Sponsor type

Industry

Conditions

Sickle Cell Disease

Interventions

Aes-103; Placebo

Participants

35

Sites

1

Countries

United Kingdom

Trials that died the same way

• Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma
  “This study was terminated early due to the Sponsor's decision to discontinue development of the investigational drug and close the program.” (80% match in meaning)
• Avelumab (Bavencio) With IL-15 in Subjects With Clear-Cell Renal Carcinoma
  “This study was terminated early due to manufacturer withdrawal of support (study medication) due to lack of enrollment.” (79% match in meaning)
• Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy
  “This study was terminated by the Sponsor.” (79% match in meaning)
• A Study to Assess Recurrence of Actinic Keratosis in Participants Treated With Methyl Aminolevulinate Hydrochloride Cream or Vehicle Cream Who Achieved Complete Response to Treated Lesions in Earlier Study
  “The study was terminated early as per Sponsor's decision” (79% match in meaning)
• Trial of Erlotinib in Patients With JAK-2 V617F Positive Polycythemia Vera
  “The study was terminated by the sponsor” (77% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.